lexicon
pharmaceuticals
host
third
quarter
financial
results
conference
call
webcast
october
woodlands
texas
globe
newswire
lexicon
pharmaceuticals
nasdaq
lxrx
release
third
quarter
financial
results
thursday
october
markets
open
management
conduct
conference
call
live
webcast
et
ct
day
discuss
financial
results
provide
clinical
update
information
number
international
number
conference
id
replay
information
number
replay
international
number
conference
id
replay
available
days
following
call
audio
webcast
available
online
events
webcast
replay
accessible
days
call
lexicon
pharmaceuticals
lexicon
biopharmaceutical
company
mission
pioneering
medicines
transform
patients
lives
program
lexicon
scientists
studied
role
function
nearly
genes
identified
protein
targets
significant
therapeutic
potential
range
diseases
precise
targeting
proteins
lexicon
pioneering
discovery
development
innovative
medicines
safely
effectively
treat
disease
lexicon
advanced
one
medicines
market
pipeline
promising
drug
candidates
discovery
clinical
preclinical
development
diabetes
metabolism
neuropathic
pain
indications
additional
information
please
visit
safe
harbor
statement
press
release
contains
statements
including
statements
relating
lexicon
financial
position
outlook
business
clinical
development
therapeutic
commercial
potential
drug
candidates
addition
press
release
also
contains
forward
looking
statements
relating
lexicon
growth
future
operating
results
discovery
development
products
strategic
alliances
intellectual
property
well
matters
historical
facts
information
statements
based
management
current
assumptions
expectations
involve
risks
uncertainties
important
factors
specifically
including
lexicon
ability
meet
capital
requirements
successfully
conduct
preclinical
clinical
development
obtain
necessary
regulatory
approvals
sotagliflozin
potential
drug
candidates
anticipated
timelines
achieve
operational
objectives
obtain
patent
protection
discoveries
establish
strategic
alliances
well
additional
factors
relating
manufacturing
intellectual
property
rights
therapeutic
commercial
value
drug
candidates
risks
uncertainties
factors
may
cause
lexicon
actual
results
materially
different
future
results
expressed
implied
statements
information
identifying
important
factors
contained
risk
factors
lexicon
annual
report
form
year
ended
december
filed
securities
exchange
commission
lexicon
undertakes
obligation
update
revise
statements
whether
result
new
information
future
events
otherwise
inquiries
chas
schultz
executive
director
corporate
communications
investor
relations
lexicon
pharmaceuticals
cschultz
